Quick Summary
- ARK Invest acquired 112,815 shares of CRISPR Therapeutics totaling approximately $5.63M through ARKK and ARKG ETFs
- The investment firm purchased 275,000 shares of PayPay Corp worth around $4.4M via its ARKF fintech ETF
- Additional purchases included GeneDx (approximately $4.43M) and Tempus AI (around $991K)
- ARK reduced holdings in Teradyne (roughly $3.3M) and Ionis Pharmaceuticals (about $3.26M)
- The firm decreased stakes in 10x Genomics and Circle Internet Group
Cathie Wood’s ARK Invest executed transactions exceeding $10 million in purchases while divesting from multiple portfolio holdings on March 12, 2026, based on the firm’s publicly disclosed daily trading activity.
CRISPR Therapeutics represented the day’s most substantial acquisition. ARK accumulated 112,815 shares distributed between two exchange-traded funds — the ARK Innovation ETF and the ARK Genomic Revolution ETF — totaling approximately $5.63 million.
CRISPR Therapeutics operates as a gene-editing biotechnology company. This acquisition demonstrates ARK’s sustained confidence in genomic medicine’s future prospects.
PayPay Corp emerged as ARK’s second-largest acquisition, representing the digital payments sector. The investment firm accumulated 275,000 shares via its ARK Fintech Innovation ETF, valued at approximately $4.4 million.
PayPay Corp experienced a 13.50% price increase during the trading session. This transaction reinforces ARK’s emphasis on fintech infrastructure and digital payment technologies.
ARK expanded holdings in two additional companies during the session. The firm acquired 52,075 shares of GeneDx, which specializes in genomic diagnostics, for approximately $4.43 million. Additionally, ARK purchased 18,820 shares of Tempus AI, an artificial intelligence healthcare data platform, valued at roughly $991,000.
ARK’s Portfolio Reductions
Regarding sales activity, ARK divested 10,919 shares of Teradyne, which manufactures chip-testing equipment, through the ARK Innovation ETF for approximately $3.3 million. Teradyne experienced a 5.09% price decline during the session.
This divestment aligns with recent activity patterns. ARK has been systematically reducing its Teradyne allocation across multiple trading days.
ARK liquidated 43,533 shares of Ionis Pharmaceuticals through its ARKG ETF, totaling approximately $3.26 million. Ionis shares declined 3.28% during the trading day.
The Ionis reduction reflects an ongoing strategy of decreasing exposure to the RNA-based pharmaceutical developer.
ARK scaled back two additional positions during the session. The firm sold 18,392 shares of 10x Genomics, a gene expression technology provider, for approximately $376,000 across ARKK and ARKG.
Additionally, ARK divested 11,194 shares of Circle Internet Group, which operates in stablecoin and blockchain payments, through ARKK for approximately $1.26 million.
Analyst Perspectives
Wall Street analysts assign GeneDx and Ionis Pharmaceuticals “Strong Buy” ratings. GeneDx presents the most significant upside opportunity among the group, approaching 100% potential appreciation.
CRISPR Therapeutics, Tempus AI, Teradyne, and 10x Genomics each receive “Moderate Buy” ratings from the analyst community. PayPay Corp maintains a “Hold” rating.
ARK completed an additional smaller transaction, acquiring 54,736 shares of Canton Strategic Holdings through its ARKF ETF, worth approximately $254,522.
